Plexxikon
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
91 Bolivar Dr Ste A, Berkeley, Californi...Phone Number
(510) 647-4000Website
www.plexxikon.comRevenue
$20.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Plexxikon
Plexxikon, a member of the Daiichi Sankyo Group since April 2011, is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The company's drug Zelboraf® (vemurafenib/PLX4032) was approved by the FDA in 2011, and Turalio® (pexidartinib/PLX3397) was approved by the FDA in 2019. Plexxikon is developing a portfolio of preclinical and clinical-stage compounds to address significant unmet medical needs in oncology and other therapeutic areas. Plexxikon's Scaffold-Based Drug Discovery platform integrates multiple state-of-the-art technologies, including the use of X-ray crystallography as an early screening tool that provides a significant advantage over other drug discovery approaches.Explore more
Plexxikon Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Plexxikon your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Plexxikon
Product Launch: Get notified when Plexxikon launches new products
Check out if Plexxikon is spiking on competitors!
Plexxikon, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Plexxikon recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check if Plexxikon has recently received funding, and reach out quickly before it becomes old news!
Click to see if Plexxikon had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Plexxikon has new funding data
Recommended Actions
Reach out to Masked Content who joined Plexxikon as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Plexxikon is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Plexxikon is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Plexxikon.
Plexxikon financials insights
Gather financial insights about Plexxikon, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2001
Series A
$8.2M
2004
Series B
$46M
Plexxikon Tech Stack
A closer look at the technologies used by Plexxikon
Most Recent Scoops
Lateral Move
Executive Move
Promotion
Executive Move
Promotion
Executive Move
Facilities Relocation / Expansion
Plexxikon is planning to move its offices in June 2021. The move will impact approximately 7 employees at their existing office located at 91 Bolivar Drive, Berkeley, CA.
Real Estate
Executive Move
Executive Moves
Plexxikon News & Media
Plexxikon Announces Key Executive Appointments; Dr. Chao Zhang Named Chief Executive ...
Plexxikon Appoints Chao Zhang, PhD, as CEO, and Marguerite Hutchinson, JD, as COO & General Counsel; Company Relocates to South San Francisco
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Plexxikon
Sign Up For FreeTo access detailed company insights
Plexxikon, a member of the Daiichi Sankyo Group since April 2011, is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The company's drug Zelboraf® (vemurafenib/PLX4032) was approved by the FDA in 2011, and Turalio® (pexidartinib/PLX3397) was approved by the FDA in 2019. Plexx... Read More
